Bendamustine plus rituximab for chronic cold agglutinin disease: results of a Nordic prospective multicenter trial

Author:

Berentsen Sigbjørn1,Randen Ulla23,Oksman Markku45,Birgens Henrik6,Tvedt Tor Henrik Anderson78,Dalgaard Jakob9,Galteland Eivind1011,Haukås Einar12,Brudevold Robert13,Sørbø Jon Hjalmar14,Næss Inger Anne15,Malecka Agnieszka216,Tjønnfjord Geir E.1117

Affiliation:

1. Department of Research and Innovation, Haugesund Hospital, Haugesund, Norway;

2. Department of Pathology, Oslo University Hospital, Oslo, Norway;

3. Department of Pathology, Akershus University Hospital, Lørenskog, Norway;

4. Department of Hematology and Stem Cell Transplantation, Division of Medicine, Turku University Hospital, Turku, Finland;

5. Department of Internal Medicine, Turku City Hospital, Turku, Finland;

6. Department of Haematology, Herlev Hospital, University of Copenhagen, Herlev, Denmark;

7. Department of Medicine, Haukeland University Hospital, Bergen, Norway;

8. Section for Hematology, Department of Clinical Science, University of Bergen, Bergen, Norway;

9. Medical Department, Drammen Hospital, Vestre Viken Trust, Drammen, Norway;

10. Department of Medicine, Akershus University Hospital, Lørenskog, Norway;

11. Department of Haematology, Oslo University Hospital, Oslo, Norway;

12. Department of Hematology and Oncology, Stavanger University Hospital, Stavanger, Norway;

13. Department of Medicine, Ålesund Hospital, Ålesund, Norway;

14. Department of Medicine, Levanger Hospital, Levanger, Norway;

15. Department of Hematology, St Olav University Hospital, Trondheim, Norway;

16. Faculty of Medicine, University of Oslo, Oslo, Norway; and

17. Institute of Clinical Medicine, University of Oslo, Oslo, Norway

Abstract

Key Points Bendamustine-rituximab therapy results in high overall and CR rates with sustained remissions in CAD. Bendamustine plus rituximab may be considered in first line for most patients with CAD requiring therapy.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Cited by 103 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3